Russian Journal of Oncology

Peer-review bimonthly medical journal.

Editor-in-chief

Journal founders

  • Izdatelstvo "Meditsyna"
  • Eco-Vector Publishing Group

Publisher

About

Since 1996 the journal publishes original articles and reviews that cover current achievements in the fields of clinical and experimental oncology as well as practical aspects of diagnosis and comprehensive treatment of malignant tumors. The journal offers insights into actual experience of cancer centers, discusses the current state of oncology research and practice outside Russia, and facilitates experience exchange. The journal also publishes medical news and material on the implementation of scientific discoveries, the most essential theoretical and practical issues, and the history of oncology.

The journal is aimed at a wide range of medical professionals: oncologists, surgeons, general practitioners, and public health officials focusing on the diagnosis and treatment of cancers.

Types of accepted articles

  • reviews
  • systematic reviews and metaanalyses
  • original research
  • clinical case reports and series
  • letters to the editor
  • short communications

Publications

  • in English and Russian
  • bimonthly, 6 issues per year
  • continuously in Online First
  • with NO Article Processing Charges (APC)
  • distribution in hybrid mode - by subscription and/or Open Access
    (OA articles with the Creative Commons Attribution 4.0 International License (CC BY-NC-ND 4.0))

Indexation

  • Russian Science Citation Index (Web of Science)
  • Russian Science Electronic Library (eLibrary.ru)
  • Google Scholar
  • Ulrich's Periodicals directory
  • WorldCat
  • Crossref

 

Announcements

 
No announcements have been published.
 
More Announcements...

Current Issue

Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

Vol 26, No 1 (2021)

Cover Page

Full Issue

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Original Study Articles

Molecular biological characteristics of tumors and results of breast cancer treatment in males
Zyuzyukina A.V., Slepov E.V., Vinnik Y.S., Zukov R.A.
Abstract

BACKGROUND: Male breast cancer is considered a rare condition – less than 1% of all breast cancer cases. 1607 cases of breast cancer were diagnosed by 2019 in Krasnoyarsk region and only 5 cases (0,31%) of the disease were in male patients.

AIM: This study aims to conduct a retrospective analysis of cases of breast cancer treatment in males in the Krasnoyarsk Territory for the period 1998–2019, as well as to assess overall and progression-free survival rates in this category of patients.

MATERIALS AND METHODS: A total of 28 males with diagnosed breast cancer received treatment at the Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky in the period from 1998 to 2019.

RESULTS: Since 2013, an increase in breast cancer in males is noted in the Krasnoyarsk Territory. Average age of the patients at the time of diagnosis was 60.3±10.3 (range – 35 to 83 years). Allocating patients to the clinical stages: 8 patients (28.6%) were diagnosed with stage I of the tumor process, stage II was revealed in 12 (42.9%) patients, stage III was diagnosed in 7 (24.9%) patients and in 1 case (3.6%) cancer was found in situ. Metastatic lesions of the lymph nodes were revealed in 11 patients (39.3%): N1 – 9 patients (81.8%), N2 – 1 patient (9.1%), N3 – 1 patient (9.1%). Luminal A subtype was diagnosed in 3 patients (13.6%), luminal B (HER2-negative) – in 16 patients (72.8%), luminal B (HER2-positive) – in 2 patients (9.1%). 75% of patients received adjuvant therapy. As a result of the treatment, stabilization of the process was registered in 64.3% of cases. 4 patients (14.3%) suffered from recurrence of the disease; 2 patients (7.1%) were diagnosed with multiple primary cancer. For the entire observation period, fatal cases composed 4 (14.3%). Analysis of the overall survival rates for the male patients with breast cancer demonstrated a positive effect of endocrine therapy.

CONCLUSION: The results obtained indicate an increase in the incidence of breast cancer in men in the Krasnoyarsk Territory. Men have the tumor which is hormone-positive and administration of hormone therapy in the adjuvant mode increases overall survival rates.

Russian Journal of Oncology. 2021;26(1):5-12
pages 5-12 views
Clinical prognostic factors for fibrolamellar liver carcinoma
Antonova E.Y., Moroz E.A., Podlyzny D.V., Kudashkin N.E., Volkov A.Y., Dzhanyan I.A., Laktionov K.K., Breder V.V.
Abstract

BACKGROUND: Fibrolamellar liver carcinoma is a rare subtype of liver cancer with an unexplored etiology. There is no information about the choice of classification for fibrolamellar liver carcinoma (FLC) in the world literature, and data on the prognostic significance of clinical aspects in FLC are very contradictory and require further study.

AIM: To evaluate the practical significance of staging systems for operable hepatocellular cancer for fibrolamellar carcinoma (TNM/AJCC, BCLC) as a separate option, to study the influence of clinical aspects (disease stage, gender, age, size of tumor) of patients with FlC on the long-term results of their treatment.

MATERIALS AND METHODS: The retrospective study included 34 patients with FlC who underwent radical surgical treatment at the first stage at the Blokhin National Research Institute of Oncology of the Ministry of Health of the Russian Federation from 2005 to 2020.

RESULTS: When assessing the prevalence of the disease according to the TNM-8/AJCC system, a significant correlation between the FlC stage and the prognosis was revealed. It is proved that the greatest RFS was achieved in the group of stages II–IIIB, while the smallest RFS was achieved in the group with stage IVB (p=0.002; p=0.000). The highest OS was achieved in the group of stages II–IIIB, while the lowest OS was achieved in the group with stage IVB (p=0.050; p=0.000). The OV of patients with FlC was not dependent

CONCLUSIONS: The TNM-8/AJCC classification optimally predicts the results of surgical treatment of FlC. The use of the Barcelona staging system for this subtype of liver cancer is impractical. The size of the primary tumor, as part of the FlC staging system, turned out to be an independent prognostic factor. The age of the patient ≥20 years correlates with the deterioration of OV.

Russian Journal of Oncology. 2021;26(1):13-22
pages 13-22 views

Case Reports

The primary B-cell lymphoma of the breast: a clinical case
Hoffman A.A., Fokeev S.D., Bakharev S.Y., Samoilenkova O.V.
Abstract

В-cell lymphoma is manifested by a variety of forms, which makes it difficult to establish an accurate lifetime diagnosis and has an unfavorable prognosis. Therefore, every case of primary B-cell lymphoma of the breast, demands attention close attention of doctors of different specialties. The feature of the presented investigation is B-cell lymphoma, that primarily affects the right breast. This type of breast cancer develops as chronic mastitis, confirming the variety of forms of its manifestation, what cause difficulties in making accurate primary diagnosis.

Russian Journal of Oncology. 2021;26(1):23-28
pages 23-28 views
A clinical case of a hereditary form of colorectal cancer associated with a CHEK2 gene defect
Minniakhmetov I.R., Bermisheva M.A., Kagirova E.M., Gordiev M.G., Khusainova R.I.
Abstract

The article describes a clinical case of colorectal cancer with a positive family history. In the course of a molecular genetic study by NGS sequencing, a germinal c.1607delC mutation was detected in exon 15 of the CHEK2 gene (NM_007194.4). According to ClinVar, this option has uncertain clinical significance. The article provides literature data on cases of carriage of CHEK2 gene mutations. More careful monitoring of carriers of pathogenic variants in the CHEK2 gene from families with multiple manifestations of colorectal cancer is now recommended.

Russian Journal of Oncology. 2021;26(1):29-34
pages 29-34 views


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies